| Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 (NCT00761449) | Nordic MDS Group | 2007-10-01 |
| Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia (NCT06211452) | Grupo Argentino de Tratamiento de la Leucemia Aguda | 2007-08-01 |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (NCT00780104) | Abramson Cancer Center at Penn Medicine | 2007-07-01 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (NCT00539695) | Baylor College of Medicine | 2007-06-01 |
| A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status (NCT00462761) | Daiichi Sankyo | 2007-01-01 |
| Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) (NCT00422591) | M.D. Anderson Cancer Center | 2006-12-01 |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies (NCT00405743) | Clavis Pharma | 2006-05-01 |
| Study of XL999 in Patients With Acute Myeloid Leukemia (AML) (NCT00322673) | Symphony Evolution, Inc. | 2006-05-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) (NCT00744081) | Goethe University | 2004-07-01 |
| High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) (NCT00707408) | Nantes University Hospital | 2004-02-01 |
| Post Transplant Donor Lymphocyte Infusion (NCT00167180) | Masonic Cancer Center, University of Minnesota | 2004-01-01 |
| Study of Bexarotene in Patients With Acute Myeloid Leukemia (NCT00316030) | Abramson Cancer Center at Penn Medicine | 2004-01-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (NCT00533923) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| Treatment Outcome in Elderly Patients (NCT00700544) | University Hospital, Grenoble | 2002-06-01 |
| DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML (NCT00589082) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2001-10-01 |
| Stem Cell Transplant for Hematological Malignancy (NCT00176930) | Masonic Cancer Center, University of Minnesota | 2001-10-01 |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies (NCT00013533) | National Cancer Institute (NCI) | 2001-03-14 |
| Stem Cell Transplantation for Hematological Malignancies (NCT00176839) | Masonic Cancer Center, University of Minnesota | 2000-06-07 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (NCT00636909) | Beth Israel Deaconess Medical Center | 1999-07-01 |
| Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders (NCT00511537) | University of California, San Francisco | 1999-01-01 |
| Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML (NCT00820976) | Turkish Leukemia Study Group | 1996-03-01 |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia (NCT00167167) | Masonic Cancer Center, University of Minnesota | 1995-12-01 |
| Flotetuzumab Expanded Access Program (NCT04678466) | MacroGenics | |
| Individual Patient Expanded Access Gilteritinib (ASP2215) (NCT03315299) | Etan Orgel | |